Mineralys Therapeutics Inc (MLYS) Stock Price, Quote & News

Company Profile

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. The company's clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. It has initiated a Phase 2...

Industry: Biotechnology

Sector: Healthcare

Phone: 888 378 6240

Website: mineralystx.com

Address:

150 N. Radnor Chester Rd., Suite F200, Radnor, United States

OptionRunners Dec. 3 at 4:10 PM

$MLYS buyer of the March 20th 2026 $40/$30/$60 bear seagulls 3,500 times for $3.35

0 · Reply

Uneducated_Trader Nov. 17 at 5:36 PM

$MLYS bought last week. Thank you mlys

0 · Reply

medguy Nov. 14 at 4:24 PM

$MLYS and $DGNX looking for reversal

0 · Reply

Arcides Nov. 14 at 3:09 PM

$MLYS standed good yesterday but today is falling on high volume.

0 · Reply

_www_larval_com_ Nov. 14 at 2:42 PM

$SGML 17%[10%] $CMBM 12%[16%] $MLYS 9%[-12%] $AVXL 9%[-34%] $TSSI -8%[-41%] most notable movement within the first minutes of trading.

0 · Reply

JarvisFlow Nov. 12 at 11:46 AM

HC Wainwright & Co. updates rating for Mineralys Therapeutics ( $MLYS ) to Buy, target set at 52 → 56.

0 · Reply

JarvisFlow Nov. 11 at 2:27 PM

Wells Fargo has adjusted their stance on Mineralys Therapeutics ( $MLYS ), setting the rating to Overweight with a target price of 50 → 55.

0 · Reply

OpenOutcrier Nov. 11 at 1:50 PM

$MLYS (-1.8% pre) Form S-3ASR Mineralys Therapeutics, https://ooc.bz/l/84089

0 · Reply

Panban Nov. 11 at 6:20 AM

$MLYS MINERALYS THERAPEUTICS INC - IN ADDITION, OFFERING OF UP TO $300 MLN OF COMMON STOCK

0 · Reply

d_risk Nov. 11 at 12:32 AM

$MLYS - Mineralys Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors MLYS drops risks tied to tariffs, inflation, and economic uncertainty, but flags new threats from potential tax law changes and possible FDA/government agency disruptions that could hit financials, product approvals, and stock value. #Biotechnology #EconomicUncertainty #FDADisruptions #TaxLawChanges #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/MLYS/10-Q/2025-11-10

0 · Reply